Binding targets of SUZ12 and EZH2 were consistently enriched across all five cancer types, while targets of REST and SMAD4 were enriched in all cancers except for clear cell renal cell carcinoma (Fig. 3d). This evidence concerns the gene REST and clear cell renal carcinoma.